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Background: The goal of this study was to develop a new method for determining tumor size to predict prognosis
with high performance in osteosarcoma.
Methods: This study was approved by the institutional review board. We retrospectively reviewed 41 magnetic
resonance (MR) images at diagnosis and 57 MR images after neoadjuvant chemotherapy from 59 patients with
non-metastatic, high-grade extremity osteosarcoma, who had undergone surgery between October 1994 and
October 2009.
Results: A new parameter of tumor axial ratio (TAR) was designed to normalize tumor size by dividing the absolute
tumor axial size by the reference bone axial size (RBS) of the affected bone. RBS was defined using anatomical
landmarks for each type of bone. Absolute tumor length (ATL), absolute tumor volume (ATV), and relative tumor
volume (RTV) were comparatively analyzed. TAR was only significantly decreased after chemotherapy in the survival
(P = 0.009) and metastasis-free (P = 0.018) group in the paired t-test. With the Kaplan–Meier method, significant
differences in overall survival (log rank P = 0.004) and disease-free survival (Log Rank P = 0.009) were noted between
decreased TAR after chemotherapy and increased TAR. After Cox regression analysis, TAR showed an odds ratios
of 5.931 for survival (95% Confidence Interval [CI], 1.153–30.513) and 14.144 for metastasis (95% CI, 2.826–70.784),
whereas ATL, ATV, and RTV showed no associations with these clinical variables. The AUC value of TAR was 0.713
(95% CI, 0.548 to 0.878) for survival and 0.759 (95% CI, 0.608 to 0.909) for metastasis.
Conclusions: TAR is a novel sizing method with potential as a prognostic tool in osteosarcoma.
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The size of a primary tumor is the most fundamental
parameter for staging solid tumors. In bone sarcomas,
the American Joint Committee on Cancer (AJCC) 7th
edition (2010) has established 8 cm in greatest dimension
as the cutoff for subclassification of stage A or B [1].
Besides AJCC staging, several studies have suggested
various tumor sizing methods and cutoff points with
prognostic powers in osteosarcoma [2-8].
Controversy over methods used to measure sizes of
bone sarcomas has arisen from two major problems.
First, there is concern over the performance of imaging* Correspondence: QSHIN@yuhs.ac
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unless otherwise stated.devices. Prior to magnetic resonance imaging (MRI),
the only two-dimensional (2D) sizing methods on
roentgenological images did not show significant results
[9]. However, significant relationships between tumor
burden (tumor volume) and prognosis have been reported
for tumor volume based on MRI [10]. Second, size
heterogeneity of the affected organ is another major
concern that is unique to bone sarcomas compared
with other cancers. The sizes of different types of bones
vary (e.g. humerus, femur, tibia, and fibula). Furthermore,
the same type of bone varies in size depending on sex and
age. Size heterogeneity is a serious concern because bone
sarcomas mainly occur in children and teenagers. For this
reason, the need for a better method to determine relative
tumor size is important.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics
Variable n (%)
5-year survival Yes 43 (72.9)
No 16 (27.1)
Metastasis rate Free 41 (69.5)
Positive 18 (30.5)
Age, mean (range) 17.8 (3–59)
Sex Male 32 (54.2)
Female 27 (45.8)
AJCC stage IIA 22 (37.3)
IIB 37 (62.7)
Site Distal femur 32 (54.2)
Proximal tibia 16 (27.1)
Proximal humerus 8 (13.6)
Proximal femur 3 (5.1)
Histology Osteoblastic 37 (62.7)
Chondroblastic 7 (11.9)
Fibroblastic 4 (6.8)
Mixed 8 (13.6)
NA 3 (5.1)
Huvos grade I and II 16 (27.1)
III and IV 43 (72.9)
Resection margin R0 58 (98.3)
R1 1 (1.7)
ALP Elevation 33 (55.9)
Normal 26 (44.1)
Abbreviations: AJCC American Joint Committee on Cancer, ALP Alkaline
phosphatase.
Table 2 Definitions of the RBS for each bone
Definition of RBS
Distal femur Longest length of the transepicondylar line†
Proximal tibia Longest length of the tibia plateau†
Proximal humerus Longest length of the anatomical neck of the
humoral head†
Proximal femur Longest length of the epiphyseal plate or vestigium
of the femoral head epiphyseal plate†
†length measured in coronal plane of MRI.
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is to normalize tumor burden according to individual
patient size (body surface area [BSA]), as described by
Bieling et al. [3]. This method, which uses an ellipsoid
formula to calculate tumor volume, was initially applied
on plain X-ray images; however modified applications on
MRI have also been reported [5,8,11]. In those studies,
there were some inherent limitations that are important to
consider. First, adjustment by BSA dose not discriminate
bias from the different types of bones involved, although it
can rule out bias from heterogeneity in individual patient
size. Second, tumor volume based on ellipsoid formulas
assumes that the shape of tumors is ellipsoidal, but this
may not always be true. Advances in MRI have led to more
correct measurement of tumor volume. Indeed, reports
based on three-dimensional (3D) volumetry of tumors have
shown prognostication of tumor burden [4,6]. However,
calculating 3D volumetry on MRI is not clinically practical.
The purpose of this study was to develop a new method
for determining tumor size with high performance for
predicting prognosis. We developed a novel method
for determining relative tumor size that focused on the
relative axial length of a tumor.
Methods
Patients
We retrospectively reviewed 41 MR images at diagnosis
and 57 after neoadjuvant chemotherapy from 59 patients
with nonmetastatic, high-grade extremity osteosarcoma,
who had undergone surgery between October 1994 and
October 2009 and analyzed them together with other
clinical data. Mean follow-up period was 114.7 months
(range, 4.8–240 months). This study was done under a
protocol approved by Severance Hospital Institutional
Review Boardl. Both MRI at diagnosis and after neoadju-
vant chemotherapy were available for 39 patients. MRI
after neoadjuvant chemotherapy but not MRI at diagnosis
was available for 18 patients. MRI at diagnosis but not
MRI after neoadjuvant chemotherapy was available for
two patients. The clinical characteristics of 59 patients are
listed in Table 1. Sixty-five patients (92.9%) had received
neoadjuvant chemotherapy. Patients were treated as
follows: 22 received combination of intraarterial cisplatin
and doxorubicin, while 37 received combination of
intraarterial cisplatin, doxorubicin, and ifosfamide.
Outcomes of neoadjuvant chemotherapy were not signifi-
cantly different between doublet and triplet regimens in
our cohorts [12].
Measurement of tumor size and novel parameter for
tumor sizing
All parameters for tumor sizing were measured on
MR images. Parameters for tumor sizing were defined
as follows: absolute tumor length (ATL), the greatestlongitudinal tumor length on either coronal or sagittal
images; absolute tumor axial size (ATA), the greatest
horizontal tumor length in any direction on axial images.
Reference bone axial size (RBS) was defined using
anatomical landmarks for each type of bone around
the epi-metaphyseal area (Table 2). Measurement of
all parameters was done with the Centricity Radiology
RA1000 program (General Electrics Healthcare, United
Kingdom). All parameters mentioned above were mea-
sured independently by three orthopaedic surgeons.
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radiologist using 3D region of interest (ROI) magnetic
resonance volumetry [13,14].
A new parameter for tumor sizing, tumor axial ratio
(TAR), was designed to normalize tumor size by
dividing ATA by RBS for each affected bone; thus,
TAR represented the ratio of tumor axial size to
affected bone axial size. The applications of our method
are illustrated in Figure 1. For example, as shown in
Figure 1a, distal femur with a RBS of 89.5 mm, and an
ATA of 84.2 mm, the TAR would be 0.94 (84.2/89.5).
Other applications for proximal tibia (Figure 1b), proximal
humerus (Figure 1c), and proximal femur (Figure 1d) are
also provided.
Statistical analysis
The reliability on measuring those parameters among
different observers was evaluated using the interclass
correlation coefficient. Changes in those parameters
after neoadjuvant chemotherapy were analyzed by the
paired t-test. Overall survival and disease-free survival
between the decreased the TAR group after neoadjuvant
chemotherapy and increased TAR were compared using the
Kaplan–Meier method and log rank test. The correlations
between each parameter and prognosis (5-year survival and
metastasis) were expressed as the hazard ratio using Cox
regression. Prognostication of TAR and ATV was com-
pared by evaluating the area under the receiver operating
characteristic curve (AUC).
All statistical analyses were performed using SPSS
(version 20.0, SPSS, Inc., Chicago, IL, USA). All P values
were two-tailed, and P < 0.05 was considered statistically
significant.Figure 1 Illustrations for applications of new relative tumor sizing method
of tumors. RBS is defined in Table 2. ATA was defined as the greatest horiz
calculated by dividing ATA by RBS. (a) RBS of distal femur that was 89.5 mm
(84.2/89.5) (b) RBS of proximal tibia that was 77.2 mm, ATA of tumor that w
humerus that was 42.5 mm, ATA of tumor that was 44.7 mm, and TAR of t
tumor that was 67.6 mm, and TAR of this case was 1.59.Results
New parameters and their reliability
To be accepted as a standard, the reliability of a method
should be evaluated. The lengths of ATL, ATA, ASA, and
RBS for all MR images enrolled in this study were
measured independently by three orthopaedic surgeons
and reliability analyses were performed (Table 3). Interclass
coefficients (ICCs) for RBS were 0.947 on MR images at
diagnosis and 0.965 on MR images after chemotherapy.
These were convincing values because RBSs were defined
from well-known and widely used anatomical landmarks.
ICCs of ATA were 0.725 on MR images at diagnosis and
0.862 on MR images after neoadjuvant chemotherapy.
Factors confounding measurement of ATA were peritu-
moral inflammatory changes and bone edema, which even-
tually resulted in the lowest ICCs on MR images at
diagnosis. The ICC of ATA on MR images after neoadju-
vant chemotherapy was increased as bone edema decreased
by neoadjuvant chemotherapy. ICCs of TAR were 0.807 on
MR images at diagnosis and 0.862 on MR images after
neoadjuvant chemotherapy. Although ICCs of TAR were
lower than those of ATL, they showed sufficient reliability.
Prognostications of parameters
Changes in parameters for tumor size after neoadjuvant
chemotherapy were analyzed by the paired t-test
(Table 4). Although there were no significant changes in
ATL, ATV, and relative tumor volume (RTV) in all groups,
ATA and TAR were significantly reduced in the survival
group (P = 0.011 and P = 0.009, respectively) and metastasis-
free group (P= 0.016 and P = 0.018, respectively). ATA and
TAR in the mortality group and metastasis-positive
group were not affected.. Dotted lines indicated RBS of each bone and solid lines indicate ATA
ontal tumor length in any direction on axial images. TAR was
, ATA of tumor that was 84.2 mm, and TAR of this case was 0.94
as 60.2 mm, and TAR of this case was 0.78 (c) RBS of proximal
his case was 1.05 (d) RBS of proximal femur that was 42.3 mm, ATA of
Table 3 Reliability for interobserver variability of various measurements on MRI
Mean ± SD Interclass correlation
(95% CI)
P
Observer 1 Observer 2 Observer 3
At diagnosis RBS (mm) 53.40 52.67 54.70 0.947 <0.001
±24.38 ±24.06 ±24.49 (0.905 to 0.972)
ATL (mm) 99.27 94.12 92.24 0.909 <0.001
±66.31 ±67.84 ±65.00 (0.840 to 0.952)
ATA (mm) 49.23 55.74 41.24 0.725 <0.001
±20.93 ±49.94 ±16.19 (0.509 to 0.855)
TAR 1.00 0.95 0.82 0.807 <0.001
±0.31 ±0.36 ±0.23 (0.652 to 0.899)
After Neoadjuvant Chemotherapy RBS (mm) 65.75 62.64 65.38 0.965 <0.001
±20.84 ±22.16 ±21.02 (0.942 to 0.979)
ATL (mm) 103.55 100.05 104.83 0.965 <0.001
±61.73 ±63.58 ±62.41 (0.944 to 0.979)
ATA (mm) 50.18 53.24 46.91 0.775 <0.001
±17.64 ±26.16 ±17.49 (0.640 to 0.865)
TAR 0.86 0.99 0.79 0.862 <0.001
±0.38 ±0.50 ±0.30 (0.775 to 0.919)
Abbreviations: SD standard deviation, CI confidence interval, RBS reference bone axial size, ATL absolute tumor length, ATA absolute tumor axial size.
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TAR group after neoadjuvant chemotherapy and increased
TAR were compared using the Kaplan–Meier method
(Figure 2). Significant differences in overall survival
(log rank P = 0.004) and disease-free survival (log rank
P =0.009) were noted.
Prognostication of all parameters was analyzed with
respect to 5-year survival and metastasis using Cox
regression analysis (Table 5). None of the parameters
on MR images at diagnosis showed associations with
survival and metastasis. However, parameters for
tumor axial extent on MR images after neoadjuvant
chemotherapy showed associations with these prognostic
variables, whereas the longitudinal extent and volume of
tumors did not. ATA showed significant associations with
prognosis (P < 0.001 for both survival and metastasis); but
the odds ratios for ATA (1.070 [95% confidence inter-
val (CI), 1.030–1.112] for survival and 1.073 [95% CI
1.035–1.112] for metastasis) revealed that they appeared to
be useless parameters in practice. However, normalization
with RBS made ATA strongly useful. TAR also showed sig-
nificant associations with survival (P = 0.033) and metasta-
sis (P = 0.001). TAR showed an odds ratio of 5.931 for
survival (95% CI, 1.153–30.513) and 14.144 for metastasis
(95% CI, 2.826–70.784). The AUC value for TAR was 0.713
(95% CI, 0.548–0.878) for survival and 0.759 (95% CI,
0.608–0.909) for metastasis, which was superior to that of
ATV (0.588 for survival [95% CI, 0.397–0.778] and 0.609
for metastasis [95% CI, 0.431–0.788]) (Figure 3). Apart
from associations with 5-years survival and metastasis, TARalso showed significant associations with histological
response to chemotherapy, with an odds ratio of
10.746 (95% CI, 1.650–69.989) in Cox regression analysis,
while the other parameters did not. In conclusion, TAR on
MR images after neoadjuvant chemotherapy was the only
parameter that predicted prognosis among parameters for
tumor size.
In consideration of clinical application, we tried to assign
cutoff values to TAR for predicting dichotomous outcomes.
The cutoff value was 0.85 for survival and metastasis,
which was derived from the Youden index. According to
dichotomous predictions validated by two-way contingency
table analysis, the accuracy, sensitivity, and specificity of
TAR for survival were 75.81% (95% CI, 0.625–0.857),
73.91% (95% CI, 0.559–0.872), and 76.92% (95% CI, 0.663–
0.848) respectively, while those for metastasis were 76.36%
(95% CI, 0.624–0.865), 72.22% (95% CI, 0.509–0.877) and
78.38% (95% C,. 0.680–0.859).
Discussion
The size of a primary tumor is regarded as a fundamental
parameter for staging solid tumors, but there has been no
proven standard method or cutoff value with high per-
formance for predicting prognosis in bone sarcomas.
Although many methods and cutoff values have been
suggested, most studies have reported on the prognostica-
tion of their sizing method using a cutoff value optimized
in their study populations. In those studies, there are still
questions regarding generalization of the cutoff values.
This study is believed to be the first to report a linear
Table 4 Paired t-tests to evaluate responsiveness to neoadjuvant chemotherapy
Total Survival Metastasis
5-year survival Death Free Positive
Mean±SD P Mean±SD P Mean±SD P Mean±SD P Mean±SD P
ATL (mm) BC 116.46 0.850 112.51 0.679 126.52 0.972 112.01 0.352 126.47 0.781
±54.67 ±54.07 ±57.53 ±55.03 ±54.85
AC 115.63 111.17 127.01 109.21 130.08
±56.30 ±60.15 ±45.61 ±60.38 ±44.77
ATV (ml) BC 174.62 0.048 174.27 0.060 175.58 0.485 174.53 0.075 174.83 0.260
±198.28 ±220.29 ±127.79 ±225.03 ±121.45
AC 119.40 103.58 163.33 104.85 154.30
±87.88 ±78.88 ±101.16 ±80.31 ±99.56
RTV (ml/m2) BC 107.86 0.059 109.32 0.074 103.83 0.463 109.49 0.092 103.96 0.241
±119.18 ±132.50 ±76.87 ±135.34 ±72.47
AC 75.47 67.95 96.35 68.88 91.28
±51.20 ±47.33 ±58.53 ±48.12 ±57.47
ATA (mm) BC 60.49 0.075 58.06 0.011 66.65 0.380 57.31 0.016 67.62 0.540
±17.11 ±18.56 ±11.18 ±18.47 ±11.18
AC 56.82 51.78 69.66 51.14 69.62
±14.88 ±12.96 ±11.63 ±12.74 ±11.09
TAR BC 0.89 0.114 0.89 0.009 0.87 0.260 0.85 0.018 0.96 0.670
±0.29 ±0.32 ±0.17 ±0.25 ±0.35
AC 0.84 0.80 0.94 0.77 0.99
±0.26 ±0.25 ±0.25 ±0.20 ±0.30
Abbreviations: SD standard deviation, BC before neoadjuvant chemotherapy, AC after neoadjuvant chemotherapy, ATL absolute tumor length, ATV absolute tumor
volume, RTV relative tumor volume, ATA absolute tumor axial size, TAR tumor axial ratio.
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size and prognosis using successive data analysis in
bone sarcomas.
Histological subtypes of osteosarcoma show distinct
effects on survival and responses to chemotherapy. InFigure 2 Overall and disease-free survival curves in decreased and increase
(Log Rank P = 0.004) and (b) disease-free survival (Log Rank P = 0.009) betwthis study, histological responses to chemotherapy
were dependent on histological subtype (osteoblastic,
chondroblastic, fibroblastic and mixed), validated by
χ2 test (P < 0.000). However, there was no significant
difference among the four subtypes for survival (P = 0.173)d TAR groups. Significant difference was noted in (a) overall survival
een the two groups.
Table 5 Cox regression to evaluate prognostication of tumor sizing parameters
5-year survival Metastasis
HR (95% CI) P HR (95% CI) P
At diagnosis (n = 41) ATL 1.005 (0.995 to 1.015) 0.324 1.005 (0.996 to 1.014) 0.291
ATV 1.000 (0.997 to 1.003) 0.918 1.000 (0.997 to 1.003) 0.955
RTV 0.999 (0.994 to 1.005) 0.839 1.000 (0.994 to 1.005) 0.871
ATA 1.019 (0.988 to 1.050) 0.232 1.024 (0.996 to 1.054) 0.099
TAR 1.031 (0.153 to 6.950) 0.975 4.748 (0.689 to 32.730) 0.114
After Neoadjuvant Chemotherapy (n = 57) ATL 1.003 (0.994 to 1.012) 0.560 1.004 (0.996 to 1.012) 0.281
ATV 1.003 (0.997 to 1.009) 0.338 1.004 (0.998 to 1.009) 0.155
RTV 1.002 (0.992 to 1.012) 0.651 1.005 (0.997 to 1.014) 0.218
ATA 1.070 (1.030 to 1.112) <0.001 1.073 (1.035 to 1.112) <0.001
TAR 5.931 (1.153 to 30.513) 0.033 14.144 (2.826 to 70.784) 0.001
Abbreviations: HR hazard ratio, CI confidence interval, ATL absolute tumor length, ATV absolute tumor volume, RTV relative tumor volume, ATA absolute tumor
axial size, TAR tumor axial ratio.
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also evaluated relationships between parameters for tumor
size and histological subtype. According to one-way analysis
of variance, among the four subtypes, only longitudinal ex-
tent, ATL, was significantly different (P = 0.020 at diagnosis,
P = 0.015 after neoadjuvant chemotherapy). Axial extent,
TAR (P = 0.238 at diagnosis, P = 0.527 after neoadjuvant
chemotherapy) and 3D ROI volume (P = 0.494 at diagnosis,
P = 0.112 after neoadjuvant chemotherapy) were not.
The significance of the axial extent of a tumor has been
considered. The Enneking staging system is also a concern
for the axial extent of a tumor [15]. Spanier et al. classified
the amount of local axial extension of osteosarcoma as sixFigure 3 Comparisons on AUC values of TAR and ATV after neoadjuvant c
survival and (b) disease-free survival.grades. Multivariate analysis has shown that only the axial
extent of a tumor has a significant effect on disease-free
survival [16]. Kim et al. reported that longitudinally growing
tumors were associated with better survival than concen-
trically growing tumors in AJCC IIB osteosarcoma [17]. On
the basis of these findings, we focused on the axial
extent of tumors. However, the application of a
method for determining the axial extent of a tumor
has limitations with respect to integration into clinical
practice. The anatomical relationships between osteo-
sarcoma and surrounding structures differ among
affected bones, so the absolute value for invasion axial
depth is not applied equally among other affected bones.hemotherapy for survival and metastasis. ROC curves for (a) overall
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tumor size has been raised, there is no established
universal standard for normalizing tumor size in
different bones. BSA is the most widely used method
for normalizing tumor size. This approach may be
suitable for normalizing tumor burden but not the
axial invasion extent of tumors because it does not
reflect axial size and spatial relationships between
tumors and affected bones. Therefore, we defined new
standards for normalizing tumor size from each
affected bone by using well-known anatomical landmarks.
This adjustment led to significant correlations with
prognosis in our study. Absolute parameters for the
axial extent of tumors did not show linear correlations
with prognosis in this study, but relative parameters did
show linear correlations with prognosis.
Many imaging modalities have been suggested to predict
response to neoadjuvant chemotherapy and oncological
outcomes. The maximum standardized uptake value
(SUVmax) on
18 F-fluorodeoxyglucose positron emission
tomography (18 F-FDG PET) has been reported as an
indicator [18-20]. 3D volumetry on MRI with greater
precisions compared with previous methods based on the
ellipsoid formula has reported reduction of tumor volume
as an indicator [4,6]. The apparent diffusion coefficient on
diffusion-weighted MRI is also an indicator [21,22]. The
major concerns with respect to these indicators are that
the values measured after neoadjuvant chemotherapy are
more convincing than the values measured at diagnosis.
In the present study, TAR showed similar results. TAR
measured on MR images at diagnosis was not prognostic,
but it was prognostic when measured after neoadjuvant
chemotherapy.
Our new method has several advantages over previous
methods. First, tumor size is normalized according to
the size of the affected bone rather than individual
patient size. Normalization with BSA does not dis-
criminate differences in the types of bones involved;
however, our method is able to distinguish differences
due to bone heterogeneity. Second, our method is easy to
use. Calculation of tumor volume using ROI-based
analysis on MR images is not practical clinically, but
our method requires only measuring the lengths of
tumors on the 2D plane of MR images. Third, our
method focuses on the extent of tumor axial growth,
which results in invasions into the surrounding tissue.
There were several limitations to our study. First,
our study was a small retrospective study and only 39
of 59 patients had both MR images at diagnosis and
after neoadjuvant chemotherapy, which may have led
to wide confidence intervals for the associations of
TAR with 5-year survival and metastasis, despite the
statistically significant P values. This study needs to
be validated in larger studies to assess applicabilityof TAR. Second, the application of our new method
was restricted to osteosarcomas located around the
epiphysis and metaphysis because RBS was defined
by anatomical landmarks around these areas. Thus, our
method cannot be applied to diaphyseal and periosteal
osteosarcomas. It is also restricted to osteosarcoma
located in large joints (shoulder, hip, and knee), although
they comprise most cases of osteosarcoma. Third, fur-
ther optimization of our method by more accurately
defining RBS should be considered. Indeed, RBS of
the proximal femur was defined as the epiphyseal
plate of the femoral head in order to decrease RBS and
increase TAR in light of poor prognosis, even though
the trochanteric area is more frequently affected than
the femoral head.
Conclusions
TAR is a novel relative sizing method with potential as a
prognostic tool in osteosarcoma, which can discriminate
differences caused by affected bone heterogeneity as well
as individual patient size.
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